Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.50 |
| ▸ | FDPS | P14324 | 2/20 | 0.50 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.48 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP14 | P50281 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.48 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4682917 | 0.82 | FDPS (0.52) | CYP11B1CYP11B2FDPSGGPS1BTN3A1 | |
| SCHEMBL4241305 | 0.82 | FDPS (0.56) | CYP11B1CYP11B2FDPSGGPS1BTN3A1 | |
| SCHEMBL13105208 | 0.80 | CYP11B1 (0.53) | CYP11B1CYP11B2FDPSGGPS1BTN3A1 | |
| SCHEMBL19200881 | 0.79 | FDPS (0.49) | CYP11B1CYP11B2FDPSGGPS1BTN3A1 | |
| SCHEMBL20798128 | 0.79 | CYP11B1 (0.44) | CYP11B1CYP11B2FDPSGGPS1BTN3A1 | |
| SCHEMBL9368910 | 0.79 | CYP11B1 (0.44) | CYP11B1CYP11B2FDPSGGPS1BTN3A1 | |
| SCHEMBL767633 | 0.77 | TBXAS1 (0.56) | CYP11B1CYP11B2FDPSTBXAS1IDH1 | |
| SCHEMBL24335704 | 0.77 | TBXAS1 (0.47) | CYP11B1CYP11B2FDPSGGPS1BTN3A1 | |
| SCHEMBL4968502 | 0.77 | FDPS (0.51) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL19199728 | 0.77 | FDPS (0.47) | CYP11B1CYP11B2FDPSGGPS1BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840549-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840549-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230365584-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHRÖDINGER, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365584-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHRÖDINGER, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | YALE UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230183213-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20220106302-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2022-04-07 | — | — | US | disclosed |
| US-20220000980-A1 | Compositions and Methods for use of CXCL12 in Treatment of Bone Disorders | UNIV NEW YORK (US) | 2022-01-06 | — | — | US | disclosed |
| US-11028078-B2 | Itraconazole analogs and use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-06-08 | — | — | US | disclosed |
| US-20210101920-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-04-08 | — | — | US | disclosed |
| US-20080287371-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR MODULATION OF THE MIGRATING MOTOR COMPLEX | TRANZYME PHARMA INC. | 2008-11-20 | — | — | US | disclosed |
| US-7446195-B2 | High affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION (US) | 2008-11-04 | — | — | US | disclosed |
| US-20080113978-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
| US-20070096106-A1 | Semiconductor display device and method of manufacturing the same | YAMAZAKI SHUNPEI | 2007-05-03 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-7169936-B2 | Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-30 | — | — | US | disclosed |
| US-7169936-B2 | Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-30 | — | — | US | disclosed |
| US-20070004757-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | ROTH GERALD J | 2007-01-04 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | MIF, ASGR1, FCGR2A | CYP11B1 1646/4885CYP11B2 1893/4885FDPS 2297/4885 |
| US-20230365584-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CDC7, BUB1B, CDK7 | CYP11B1 3476/4885CYP11B2 3838/4885FDPS 1764/4885 |
| US-20070004757-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | KDR, FLT1, EGFR | CYP11B1 309/4885CYP11B2 386/4885FDPS 4040/4885 |
| US-20230183213-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | HCCS, HAVCR2, MAVS | CYP11B1 1644/4885CYP11B2 1999/4885FDPS 1293/4885 |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | CRHR1, CRHR2, CRH | CYP11B1 367/4885CYP11B2 340/4885FDPS 4253/4885 |
| US-11840549-B2 | Bisphosphonate quinolone conjugates and uses thereof | BPGM, PHPT1, NQO2 | CYP11B1 970/4885CYP11B2 879/4885FDPS 53/4885 |
| US-20220000980-A1 | Compositions and Methods for use of CXCL12 in Treatment of Bone Disorders | CXCL12, CXCR4, SDF4 | CYP11B1 2570/4885CYP11B2 2896/4885FDPS 3348/4885 |
| US-20220106302-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | CYP3A4, SHH, GLI1 | CYP11B1 61/4885CYP11B2 72/4885FDPS 1333/4885 |
| US-20080113978-A1 | Imidazopyridazine Compounds | CRHR1, CRH, CRHR2 | CYP11B1 168/4885CYP11B2 173/4885FDPS 2320/4885 |
| US-11028078-B2 | Itraconazole analogs and use thereof | SHH, GLI1, KDR | CYP11B1 1205/4885CYP11B2 726/4885FDPS 2802/4885 |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | CDKL2, CDK2, CDKL1 | CYP11B1 3684/4885CYP11B2 3093/4885FDPS 1055/4885 |
| US-20210101920-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BPGM, PHPT1, NQO2 | CYP11B1 970/4885CYP11B2 879/4885FDPS 53/4885 |
| US-20080287371-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR MODULATION OF THE MIGRATING MOTOR COMPLEX | MLNR, CCKAR, CCKBR | CYP11B1 1936/4885CYP11B2 1924/4885FDPS 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.